Emese Zsiros is an Oncology physician affiliated with Roswell Park Comprehensive Cancer Center. OpenAlex indexes 197 publications with 3,791 citations (h-index 28); ClinicalTrials.gov lists 12 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Elm And Carlton St
Buffalo, NY 142630001
Telephone
716-845-2300Provider last certified this registry record 15 Feb 2021.
Clinical trials
- GB-5267 for the Treatment Platinum-Resistant Ovarian, Peritoneal, or Fallopian Tube Cancer
Sponsor: Roswell Park Cancer Institute
- Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer
Sponsor: Roswell Park Cancer Institute
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
5 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ABBVIE INC.Program year202510 payments
- Merck Sharp & Dohme LLCProgram year20253 payments
- Merck Sharp & Dohme LLCProgram year20243 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
NIH funding
1 NIH research award on record, funded 2022–2026 per NIH RePORTER. The latest:
- Targeting complement to enhance antitumor immunity and control malignant effusions in patients with recurrent epithelial ovarian cancer
Roswell Park Cancer Institute Corp
FY2026$663,819R01CA267690 - Targeting complement to enhance antitumor immunity and control malignant effusions in patients with recurrent epithelial ovarian cancer
Roswell Park Cancer Institute Corp
FY2025$642,760R01CA267690 - Targeting complement to enhance antitumor immunity and control malignant effusions in patients with recurrent epithelial ovarian cancer
Roswell Park Cancer Institute Corp
FY2024$618,854R01CA267690
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- NCCN Guidelines® Insights: Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer, Version 3.2024
Journal of the National Comprehensive Cancer Network
2024 - Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer
Journal for ImmunoTherapy of Cancer
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Philip McCarthy, MD
Roswell Park Comprehensive Cancer Center
Saby George, MD
Roswell Park Comprehensive Cancer Center
Eunice Wang, MD
Roswell Park Comprehensive Cancer Center
Shashikant Lele, MD
Roswell Park Comprehensive Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”